^
    Back
    Association details:
    Biomarker:BRAF V600M
    Cancer:Melanoma
    Drug:navtemadlin (KRT-232) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

    Excerpt:
    …BRAFV600E/M PDXs exhibited a synergistic response to the combination of KRT-232 and BRAF/MEK inhibitors.
    Secondary therapy:
    MEK inhibitor; BRAF inhibitor
    DOI:
    10.1158/1078-0432.CCR-19-1895